The present invention relates to the use of mimotopes in the treatment of diseases associated with ß-amyloid formation and/or aggregation (ß-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to Aßl-40/42, AßpE3-40/42, Aß3-40/42 and Aßll-40/42.
